DFC
RXRX icon

DBK Financial Counsel’s Recursion Pharmaceuticals RXRX Stock Holding History

DBK Financial Counsel’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$79.3K – 54
2025
Q1 		$79.3K Hold
15,000
– – 0.08% 50
2024
Q4 		$101K Buy
+15,000
New +$101K 0.1% 51

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

DBK Financial Counsel's RXRX Position: Q2 2025 in Review

DBK Financial Counsel sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 15,000 shares — an estimated $79.3K sold.

DBK Financial Counsel first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $101K in Q4 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • DBK Financial Counsel reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • DBK Financial Counsel sold 15,000 Recursion Pharmaceuticals shares in Q2 2025, an estimated $79.3K.
  • DBK Financial Counsel first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • DBK Financial Counsel's Recursion Pharmaceuticals position peaked at $101K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on DBK Financial Counsel's 13F filing for Q2 2025, filed 22 Jul 2025.